ArticleInflammation2026
Mast Cell Chymase and Human Lung Fibroblast Interaction: Mechanisms and Implications for Asthma.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cells play a crucial role in the pathogenesis of asthma, by releasing inflammatory mediators including mast cell-specific proteases such as tryptase and chymase. However, the exact role of these proteases in asthma is not fully understood. We showed previously that chymase imposes multiple effects on primary human lung fibroblasts (HLFs), and in the present report we addressed the underlying mechanisms. The effects of chymase on HLFs were found to be independent of protease-activated receptors (PARs), as judged by employing PAR agonists and antagonists, despite PAR1 and PAR3 being highly expressed. Further, Western blot analysis revealed that chymase degraded fibronectin and affected the levels and phosphorylation status of multiple signalling factors related to fibronectin, including integrin αVb3, focal adhesion kinase, Src and Akt. This was associated with a decreased motility of chymase-treated HLFs, as assessed by a cell migration assay. Chymase treatment also suppressed the levels and/or the phosphorylation status of CREB and c-Jun. Intriguingly, chymase was shown to induce the degradation of HSP27, an intracellular protein, suggesting that chymase may exert proteolytic activity in the cell interior. In agreement with this, confocal microscopy analysis revealed that chymase was taken up by the HLFs. By using Seahorse technology, we also demonstrate that chymase has the capacity to suppress the metabolic activity of HLFs, without causing cell death. Altogether, these findings reveal a novel role for mast cell chymase in affecting signalling pathways in HLFs, thereby providing insight into how mast cells potentially can affect the lung microenvironment in asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.